louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02829333: The Effect of Anesthetic Technique on VEGF-C and PGE2
Official title: Effect of Anesthetic Technique on Serum Vascular Endothelial Growth Factor C and Prostaglandin E2 in Women Undergoing Surgery for Uterine Leiomyomas
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Uterine Leiomyomas
Keywords: analgesia
anesthesia
leiomyomas
tumor
vascular endothelial growth factor
anesthesia technique on tumor
Lead sponsor: General Hospital of Ningxia Medical University
Sponsor class: OTHER
First posted: 2016-07-12
Enrollment: 44
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to verify the effect of anesthetic technique on the change of postoperative serum vascular endothelial growth factor C and prostaglandin E2, and to explore the potential impact of the anesthetic technique on leiomyomas recurrence and growth after the surgery of abdominal myomectomy.

Detailed description: Uterine leiomyomas is the most common benign tumor of uterus, the most common tumor in women as well. Like many other forms of tumor, it requires an independent blood supply to enlarge. This process, angiogenesis, is mediated by vascular endothelial growth factor C (VEGF-C) and prostaglandin E2 (PGE2). Several studies have confirmed that VEGF-C has a high level in patients with uterine leiomyomas, which has also been demonstrated that it was related to occurrence and growth of uterine leiomyomas because it's capable of promoting angiogenesis, mitogenic, and vascular permeability-enhancing activities. Also, some researchers suggested that suppression of prostaglandin synthesis (including PGE2) via cyclooxygenase type-2 (COX-2) enzyme inhibition may reduce the incidence of some tumor. The aim of this study is to verify the effect of anesthetic technique on the change of postoperative serum VEGF-C and PGE2, and to explore the potential impact of the anesthetic technique on leiomyomas recurrence and growth after the surgery of abdominal myomectomy.

Eligibility criteria: Inclusion Criteria:

* The patients with leiomyomas requiring abdominal myomectomy, aged 18-65 year and American Society of Anesthesiologists (ASA) physical status I or II.

Exclusion Criteria:

* The patients who had a history of surgery within the preceding two weeks, a history of blood transfusion and a history of coronary artery disease, any contraindication to spinal anesthesia or opioid analgesia.

Primary outcomes:
measure: Change of vascular endothelial growth factor C before anesthesia and at 48 hours after surgery
timeFrame: Before anesthesia and at 48 hours after surgery
measure: Change of prostaglandin E2 before anesthesia and at 48 hours after surgery
timeFrame: Before anesthesia and at 48 hours after surgery
Secondary outcomes:
measure: Visual analog scale (VAS) pain scores
timeFrame: at 2h, 4h, 8h, 12h, 24h and 48h after surgery
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02644733: Effect of Different Body Position on Intraabdominal Pressure in Mechanically Ventilated Patients
Official title: Lecturer in Critical Care Nursing Department
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Intraabdominal Hypertension
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2016-01-01
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: adult mechanically ventilated patients

Brief summary: Measuring intraabdominal pressure in the semi-recumbent position and supine position.

Detailed description: Each set of measurements of intraabdominal pressure included intra bladder and intragastric pressure in the supine position followed by the semi-recumbent position at head of bed 30. All four measurements were taken over a period of 5 to 10 min or less to reduce the possibility of changes in intraabdominal pressure over time. Three sets of readings were taken at least 4 h apart over a 24-h period.

Eligibility criteria: Inclusion Criteria:

older than 18 years of age. to be sedated mechanically ventilated and to have both a nasogastric tube and indwelling urine catheter in place

Exclusion Criteria:

* recent oesophageal, gastric or bladder surgery; patients who were moribund and unlikely to survive 24 h; patients who were pregnant and patients who were unable to lay flat for any reason.

Primary outcomes:
measure: determine the effect of different body position on the intraabdominal pressure
timeFrame: up to 24 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Egypt
country: Egypt
facility: Faculty of Nursing
state: Assuit
city: Assuit
country: Egypt
facility: Assuit university hospital
Study officials:
affiliation: Assuit university hospital
name: Ghada Sh Khalaf, Lecturer
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rooban N, Regli A, Davis WA, De Keulenaer BL. Comparing intra-abdominal pressures in different body positions via a urinary catheter and nasogastric tube: a pilot study. Ann Intensive Care. 2012 Jul 5;2 Suppl 1(Suppl 1):S11. doi: 10.1186/2110-5820-2-S1-S11. Epub 2012 Jul 5.
Clinical trial NCT00735033: The Effects of the Swiss Ball on Cerebral Vascular Accident
Official title: The Effects of the Swiss Ball on Patients With Hemiplegia Due to Cerebral Vascular Accident
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hemiplegia
Cerebrovascular Accident
Keywords: Physical therapy
Physical therapy modalities
Cerebral Vascular Accident (CVA)
Lead sponsor: Fortaleza University
Sponsor class: OTHER
First posted: 2008-08-14
Sex: ALL
Minimum age (years): 19
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Primary purpose: TREATMENT

Brief summary: The objective of this study was to investigate the effects of the Swiss ball on patients with hemiplegia due to CVA.

Detailed description: The Cerebral Vascular Accident (CVA) is a neurological deficit, which may be transitory or definite, leading to motor, psychological and social alterations. It's the third cause of death in the industrialized world, of which 90% of the survivors have some residual deficit and 30% become disabled. The objective of this study was to investigate the effects of the Swiss ball on patients with hemiplegia due to CVA. An intervening and controlled study was conducted on 12 patients of both genders and over 50 years old with chronic hemiplegia, all undergoing treatment at the Beneficent Rehabilitation Association of Ceará. The patients in the experimental group (EG) underwent treatment with the Swiss ball added to conventional physical therapy and the control group (CG) went through conventional physiotherapy sessions. The treatment was done twice a week, consisting of 14 sessions altogether. The data were collected in an evaluation form at the beginning and at the end of the treatment. Most patients were found to be males; they had typical walking ability, tonus, and posture of chronic hemiplegia patients. The patients in the experimental group showed significantly greater muscular strength on the lower limbs than the control group (p \< 0,05, Student t test), however, the same did not happen in the case of the other parameters, such as strength on the upper limbs, coordination, and balance. We can conclude that the treatment with the Swiss ball can promote increased strength, which will allow for a more efficient recovery in the studied population.

Eligibility criteria: Inclusion Criteria:

* Hemiplegia due to CVA
* In physiotherapy treatment
* Acceptance in join the research

Exclusion Criteria:

* Less then 6 months of diagnostic

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01347333: Stereotactic Body Radiotherapy for Liver Tumors
Official title: Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Liver Metastases and Primary Liver Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Liver Metastases
Hepatocellular Carcinoma
Intrahepatic Cholangiocarcinoma
Keywords: liver metastases
stereotactic radiotherapy
Lead sponsor: Mercy Research
Sponsor class: OTHER
First posted: 2011-05-04
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy for the treatment of liver metastases and unresectable primary liver tumors such as hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Detailed description: This study is a single site, non-randomized, prospective, phase IV trial.

Composed of 4 patient groups:

1. Oligometastases (1-3) with aggregate tumor diameter \< 6 cm
2. Metastases from neuroendocrine tumors with functional endocrine syndromes
3. Unresectable hepatocellular carcinoma (HCC)
4. Unresectable intrahepatic cholangiocarcinoma (IHCC) Data collected will include patient demographics, pathology data, tumor stage, SBRT dose fractionation scheme, dose received by adjacent critical normal tissues, tumor recurrence data, and acute and late toxicities. Follow up data will be collected during the patient's standard office visits. The anticipated duration of this study is 5 years.

Eligibility criteria: Inclusion Criteria:

* Patient age \>= 18 years
* Zubrod performance status of 0-3
* Oligometastases (1-3) with aggregate tumor diameter \< 6 cm
* Metastases from neuroendocrine tumors with functional endocrine syndromes for symptom palliation
* Unresectable hepatocellular carcinoma (HCC)
* Unresectable intrahepatic cholangiocarcinoma (IHCC)
* Maximum tumor diameter \< 6 cm
* Adequate liver function:

Total bilirubin \< 3 mg/dL Serum albumin \> 2.5 g/dL Serum levels of liver enzymes \< 3 times the upper limit of normal Normal PT and PTT unless patient is receiving anticoagulant medication

- Signed study-specific consent form

Exclusion Criteria:

* Maximum tumor diameter \> 6 cm
* Prior radiotherapy to the liver
* Pregnant or lactating women, due to potential exposure of the fetus to RT and unknown effects of RT on lactating females
* Patients with psychiatric or addictive disorder that would preclude obtaining informed consent

Primary outcomes:
measure: Local Tumor Recurrence Rate
timeFrame: 5 years
Secondary outcomes:
measure: Late Complication Rates
timeFrame: 5 years
Other outcomes:
Locations:
city: Saint Louis
country: United States
facility: St. John's Mercy Medical Center
state: Missouri
Study officials:
affiliation: Mercy Hospital St. Louis
name: Bethany G Sleckman, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01823133: Study for Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Rosuvastatin
Official title: A Randomized, Open Label Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Rosuvastatin in Healthy Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: LG Life Sciences
Sponsor class: INDUSTRY
First posted: 2013-04-04
Enrollment: 30
Sex: MALE
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Investigate the pharmacokinetic drug interactions between gemigliptin and rosuvastatin in healthy subjects


Eligibility criteria: Inclusion Criteria:

* Age between 20 to 45, healthy male subjects (at screening)
* BMI between 18 - 27 kg/m2 (at screening)
* Blood pressure SBP 90-140 mmHg, DBP 60-95 mmHg
* FPG 70-125mg/dL glucose level (at screening)
* Subject who totally understand the progress of this clinical trials, make decision by his free will, and signed a consent form to follow the

Exclusion Criteria:

* Subject who has past or present history of any diseases following below.(liver including hepatitis virus carrier, kidney, Neurology,immunology,pulmonary,endocrine,hematooncology,cardiology,mental disorder.)
* Subject who had GI tract disease that influencable to drug absorption or(ulcer, acute or chronic pancreatitis) surgery.(appendectomy, hernioplasty are not included)
* Subject who had drug hypersensitivity reaction.(gemigliptin, rosuvastatin, aspirin, antibiotics)
* Subject who already admitted in other investigator product in 80 days
* Subject who had whole blood donation in 60 days, or component blood donation in 30 days or transfusion in 30 days currently

Primary outcomes:
measure: Cmax
timeFrame: up to 72 hour post dose
measure: AUC
timeFrame: up to 72 hour post dose
Secondary outcomes:
measure: Tmax
timeFrame: up to 72 hour post dose
measure: Cmin
timeFrame: upto 72 hour post dose
measure: t1/2β
timeFrame: upto 72 hour post dose
measure: Cmax
timeFrame: upto 72 hour post dose
measure: AUC
timeFrame: upto 72 hour post dose
measure: metabolic ratio
timeFrame: upto 72 hour post dose
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
References:
citation: Choi HY, Lim HS, Kim YH, Jeon HS, Kim MJ, Lee SH, Jung JH, Lee YK, Kim HJ, Bae KS. Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects. Curr Med Res Opin. 2015 Feb;31(2):229-41. doi: 10.1185/03007995.2014.980886. Epub 2014 Nov 6.
Clinical trial NCT07015333: Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab
Official title: Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Oral Squamous Cell Carcinoma (OSCC)
Lead sponsor: Commonwealth Healthcare Corporation
Sponsor class: OTHER
First posted: 2025-06-11
Enrollment: 31
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with advanced betel nut-induced oral cancer

Brief summary: Chart review of records of patients treated for betel nut-induced oral cancer with pembrolizumab and cetuximab.


Eligibility criteria: Inclusion Criteria:

* Advanced betel nut-induced oral cancer

Exclusion Criteria:

* None

Primary outcomes:
measure: Objective Response Rate (ORR)
timeFrame: From date first treatment received until 3 months later
Secondary outcomes:
Other outcomes:
Locations:
city: Saipan
country: Northern Mariana Islands
facility: CHCC
Study officials:
References:
Clinical trial NCT01173133: Skin Flap Visible Light Spectroscopy (VLS) Oximetry for Monitoring Free-Flap Ischemia During Breast Reconstruction and Recovery
Official title: Skin Flap Visible Light Spectroscopy (VLS) Oximetry for Monitoring Free-Flap Ischemia During Breast Reconstruction and Recovery
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Ischemia
Keywords: Free Flap
Surgery
Ischemia
Outcome
Reconstructive Plastic Surgery
Monitoring
Lead sponsor: Spectros Corporation
Sponsor class: INDUSTRY
Collaborators: name: Mills-Peninsula Medical Center
name: Stanford University
First posted: 2010-07-30
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing surgical breast reconstruction.

Brief summary: The purpose of the study is to understand the relevance of tissue oximetry measures of tissue flaps during surgery and during recovery, and to determine if T-Stat is a reliable and early method of detecting compromised flaps.

Detailed description: The tissue saturation of free flaps will be measured before, during, and after surgery and during recovery.

Eligibility criteria: Inclusion Criteria:

* Under surgical breast reconstruction
* Informed consent

Exclusion Criteria:

* Failure to give consent

Primary outcomes:
measure: Flap Failure and Compromise by Tissue Saturation Values (Efficacy)
timeFrame: 72 hours
Secondary outcomes:
measure: Oximetric Diagnosis compared to Clinical Diagnosis, Doppler
timeFrame: 72 hours
measure: Device Safety Measures (safety)
timeFrame: 72 hours
Other outcomes:
Locations:
city: Burlingame
country: United States
facility: Mills Penisula Hospital
state: California
Study officials:
References:
Clinical trial NCT01648933: Perfusion Analysis Using Rubidium in Cardiac Sarcoidosis
Official title: Perfusion Analysis Using Rubidium in Cardiac Sarcoidosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sarcoidosis
Keywords: sarcoidosis
heart
Rubidium
PET
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2012-07-25
Enrollment: 53
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The study aims at assessing diagnostic and therapeutic impact of Rubidium-82 PET in cardiac sarcoidosis.

Detailed description: The presence of cardiac involvement is a serious complication of sarcoidosis. Early diagnosis is challenging since it relies on an array of clinical, biological and imaging abnormalities. Myocardial perfusion imaging with sestamibi is currently a major feature of the diagnosis, since it allows to evidence both microcirculatory impairments and scar. However, some technical limitations are inherent to SPECT, mainly poor spatial resolution and lack of attenuation correction, resulting in the absence of flow quantification. Rubidium-82 (Rb) PET proved to be more sensitive and specific than sestamibi SPECT in the diagnosis of coronary artery disease. Furthermore, it allows noninvasive measurement of coronary flow reserve. Finally, it exposes patients to lower radiation dose than SPECT. Therefore, Rb PET may help to better identify cardiac involvement of sarcoidosis, and hence to better select those patients who require high-dose steroids.

Eligibility criteria: Inclusion Criteria:

* (1) histologically proven sarcoidosis;
* (2) suspicion of cardiac involvement on symptoms, and/or ECG and/or echocardiogram.

Exclusion Criteria:

* patient \< 18 years old

Primary outcomes:
measure: percentage of patient who has two different diagnostic and therapeutic attitude before knowing Rubidium-82 PET result and after knowing Rubidium-82 PET result
timeFrame: 60 days
Secondary outcomes:
measure: Analysis of the cost for the use of Sestamibi SPECT and Rb-PET as MPI agents in cardiac sarcoidosis.
timeFrame: 9 months
Other outcomes:
Locations:
city: Paris
country: France
facility: Groupe Hospitalier Bichat - Claude Bernard 46, rue Henri-Huchard
state: Ile De France
Study officials:
affiliation: Assistance Publique - Hôpitaux de Paris
name: Dominique Le Guludec, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06946433: Phase 1 RCT of tDCS in Adults With ASD and/or ADHD Without Intellectual Disability
Official title: Ensayo clínico Fase 1 de tDCS en Adultos Con TEA y/o TDAH Sin Discapacidad Intelectual
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Autism Spectrum Disorder
Attention Deficit Disorder With Hyperactivity
Keywords: tdcs
autism
adhd
Lead sponsor: Hospital Universitari Vall d'Hebron Research Institute
Sponsor class: OTHER
First posted: 2025-04-27
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to learn about the safety and tolerability of transcranial direct current stimulation (tDCS) combined with cognitive training in adults with Autism Spectrum Disorder (ASD) and/or Attention-Deficit/Hyperactivity Disorder (ADHD).

The main question it aims to answer is:

Is tDCS safe and well-tolerated in adults with ASD and/or ADHD?

Researchers will compare active tDCS to a sham (placebo-like) stimulation to evaluate safety and tolerability.

Participants will:

Receive either active or sham tDCS for 20 minutes daily over 10 consecutive workdays

Undergo stimulation with the anode placed at F3 and the cathode at Fp2

Complete daily cognitive training exercises using the NeuronUP platform during stimulation

Attend baseline and follow-up assessments to monitor for any side effects or discomfort related to the intervention


Eligibility criteria: Inclusion Criteria:

Adults aged 18 to 55 years

Clinical diagnosis of Autism Spectrum Disorder (ASD) and/or Attention-Deficit/Hyperactivity Disorder (ADHD) confirmed via medical records or structured clinical interview

Able to provide informed consent

Fluent in the language used for assessments and cognitive training tasks

Stable medication regimen (if applicable) for at least 4 weeks prior to enrollment

Willing and able to attend 10 consecutive weekday sessions and follow-up assessment

Exclusion Criteria:

History of epilepsy, seizures, or significant neurological disorder (e.g., traumatic brain injury, stroke)

Current diagnosis of psychotic disorder or bipolar disorder

Presence of metal implants in the head (excluding dental work), pacemaker, or other contraindications to tDCS

Current substance use disorder (within past 6 months)

Pregnant or planning to become pregnant during the study period

Participation in another intervention study within the last 30 days

Any condition that, in the opinion of the investigators, may make participation unsafe or interfere with study procedures

Primary outcomes:
measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
timeFrame: Throughout the 10-day intervention period and at follow-up (up to 2 weeks post-intervention)
Secondary outcomes:
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital Universitari Vall d'Hebron
Study officials:
References: